Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06510374
Title Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer (ABLE-32)
Acronym ABLE-32
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Ferring Pharmaceuticals
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.